Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,988 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06928389RecruitingPhase 3
Ivonescimab plus docetaxel for advanced lung cancer
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06929936RecruitingPhase 2
Trilaciclib plus docetaxel for advanced lung cancer (second-line+)
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
Xiamen, FujianAges 18 years+ - NCT06934343Recruiting
Personalized therapy for advanced lung cancer using data
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
Salt Lake City, UtahAges Any age - NCT06936878Recruiting
BOLSTER: Learning skills to thrive with advanced cancer
This study tests a program called BOLSTER to help you learn new skills to thrive while managing advanced cancer and a complex care need. You and a family caregiver will participate together.
Boston, MassachusettsAges 18 years+ - NCT06937034Recruiting
Study of foslevodopa/foscarbidopa for advanced Parkinson's
This study observes how well a new type of levodopa/carbidopa treatment works in real-world practice for people with advanced Parkinson's disease who are already using it. It aims to understand patient experiences and the support program offered by the drug maker.
Graz, StyriaAges 18 years+ - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT06937905RecruitingPhase 3
Tarlatamab vs chemo for advanced NEC after one prior treatment
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
AngersAges 18 years+ - NCT06938321RecruitingPhase 1/Phase 2
New drug combo for advanced bile duct and gallbladder cancer
This trial tests two new drugs, AK130 and AK112, for people with advanced bile duct or gallbladder cancer that has stopped responding to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06940102Recruiting
A study on megestrol acetate for weight loss in advanced digestive cancer
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
Shenyang, LiaoningAges 18 years+ - NCT06940180RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for sinus cancer
This trial tests a combination of an immunotherapy drug (toripalimab) plus chemotherapy before surgery for sinus cancer that has not spread. The goal is to see if this treatment shrinks the tumor so surgery can be more effective.
Boston, MassachusettsAges 18 years+ - NCT06940518RecruitingPhase 2
Ivonescimab for advanced clear cell kidney cancer
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT06940739RecruitingPhase 1/Phase 2
IOV-3001 and lifileucel for advanced melanoma
This trial tests a new combination treatment, IOV-3001 and lifileucel, for people with advanced melanoma that has not responded to standard immunotherapy and cannot be surgically removed. It aims to see if this cellular therapy is safe and effective.
Denver, ColoradoAges 18–70 - NCT06941662Recruiting
Huntington's disease biobank: remote monitoring study
This study is building a biobank to better understand Huntington's disease by using remote monitoring and deep phenotyping (collecting detailed health information). It may help develop better ways to track the disease and improve care for people with the Huntington's gene expansion.
Palo Alto, CaliforniaAges Any age - NCT06942143RecruitingPhase 1
Super1 TCR-T for NY-ESO-1 positive advanced solid tumors
This trial tests an experimental treatment called Super1 TCR-T, which is a type of immunotherapy designed to attack tumors that have a specific protein (NY-ESO-1). It is for people with advanced solid tumors whose first treatment has stopped working and who also have a certain genetic marker (HLA-A*02).
Guangzhou, GaungdongAges 18–75 - NCT06942442RecruitingPhase 2
Tebentafusp for advanced clear cell sarcoma
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
Los Angeles, CaliforniaAges 18 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06944444RecruitingPhase 1
Testing a new drug for advanced tumors
This trial tests a new drug, SSS59, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and how it affects the body.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06944457RecruitingPhase 1
Safety Study of MPD-1 for Advanced Solid Tumors
This trial tests a new drug called MPD-1 for people with advanced solid tumors that have not responded to standard treatments. It focuses on patients with specific genetic changes (KRAS mutation or PTEN loss) to see if the drug is safe and how the body processes it.
SeoulAges 19–75 - NCT06945718Recruiting
Green dye test for gastric cancer surgery
This trial tests whether a green dye called indocyanine green can help surgeons find and remove more lymph nodes during laparoscopic surgery for advanced stomach cancer. It may improve the chances of removing all cancer.
Fuzhou, FujianAges 18–75 - NCT06946615RecruitingPhase 1
Claudin18.2 cell therapy for advanced colorectal cancer
This study tests a new treatment using your own immune cells (called CAR-T and CAR-DC) that are engineered to attack cancer cells with a specific protein (Claudin18.2). It is for people with advanced colorectal cancer who have exhausted standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT06946771Recruiting
MRI and prostate lesions: understanding diagnosis and prognosis
This trial uses MRI scans to study prostate lesions and see how they relate to diagnosis, pathology, and long-term outcomes. It may help patients with concerns about prostate health get more detailed imaging.
Wuhan, HubeiAges 18 years+ - NCT06949033RecruitingPhase 3
Cadonilimab with chemo for stomach cancer
This trial tests a new combination of immunotherapy (cadonilimab) and chemotherapy before and after surgery for a specific type of advanced stomach or gastroesophageal junction cancer. It aims to see if adding this immunotherapy helps shrink tumors and improve outcomes.
Lanzhou, GansuAges 18–75 - NCT06949410RecruitingPhase 1
HER2 vaccine study for high-risk breast cancer
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Indianapolis, IndianaAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,988 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.